GTx's Toremifene 80 Mg Increased Bone Mineral Density In Multiple Clinically Relevant Subpopulations Of Prostate Cancer Patients
GTx, Inc. (Nasdaq: GTXI) announced the presentation of data demonstrating that toremifene 80 mg treatment compared to placebo increased bone mineral density (BMD) in multiple clinically relevant subpopulations of men with prostate cancer on androgen deprivation therapy (ADT). The data, an analysis of results of the recent Phase III clinical trial evaluating toremifene 80 mg for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer, were presented yesterday at the 2009 Annual Meeting of the American Society of Clinical Oncology.
Sexual Health
Pages: 1 [2]
Results From A European Caregiver Survey Highlight The Impact Of Attention Deficit Hyperactivity Disorder (ADHD) On The Child And The Family
2000:85-93. 9. International Classification of Diseases, 10th ed., (ICD-10). World Health Organization; 2007:Chapter 5,F90. Available here. 10. Taylor E, et al. European Clinical Guidelines for Hyperkinetic Disorder - First Upgrade. Eur Child Adolesc Psychiatry [Supplement 1]. 2004;13:i7-i30. Shire Plc.Pages: 1 [2]